Does Wisconsin Medicaid cover GLP-1s for weight loss?
Does Wisconsin Medicaid cover GLP-1s for weight loss?
Wisconsin Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The published threshold is: 30 or more; or 27 to 29 with two or more of dyslipidemia, hypertension, sleep apnea, type 2 diabetes, and cardiovascular disease evidenced by a heart attack, coronary revascularization, angina, stroke, claudication with an ankle-brachial index of 0.9 or less, peripheral arterial revascularization or an amputation for atherosclerotic disease. At 12–17, Saxenda needs body weight above 132 lb and a BMI matching 30 for adults; orlistat, phentermine/topiramate, Wegovy and Xenical need the 95th percentile standardized for age and gender. Last checked 2026-09-05.
What the prior authorization asks for
- BMI threshold
- 30 or more; or 27 to 29 with two or more of dyslipidemia, hypertension, sleep apnea, type 2 diabetes, and cardiovascular disease evidenced by a heart attack, coronary revascularization, angina, stroke, claudication with an ankle-brachial index of 0.9 or less, peripheral arterial revascularization or an amputation for atherosclerotic disease. At 12–17, Saxenda needs body weight above 132 lb and a BMI matching 30 for adults; orlistat, phentermine/topiramate, Wegovy and Xenical need the 95th percentile standardized for age and gender.
- Tried first
- A weight loss treatment plan — diet, exercise or nutritional counseling — in the past six months
- Age
- 18 and over for anti-obesity drugs generally; 12 and over for Evekeo, orlistat, phentermine/topiramate, Saxenda, Wegovy and Xenical.
Those six — Evekeo, orlistat, phentermine/topiramate, Saxenda, Wegovy and Xenical — are the only products the form names anywhere, as the agents a member under 18 may be approved for. Zepbound appears nowhere in Wisconsin's anti-obesity prior-authorization attachment.
Both tools fill from these criteria rather than from a template — a prior authorization for Wisconsin, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Wisconsin decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: Prior Authorization Drug Attachment for Weight Management Agents (F-00163) , effective 2025-11-01. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Wisconsin can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.